Survival for women with advanced ovarian cancer may be negatively impacted when chemotherapy is initiated more than 25 days after surgery, a new study published online ahead of print in the journal Annals of Oncology has shown.1
For the study, researchers sought to evaluate whether time elapsed between surgery and initiation of chemotherapy affects survival in patients with advanced ovarian carcinoma.
Researchers conducted a posttrial ad hoc analysis of Gynecologic Oncology Group protocol 218, a randomized, double-blind, placebo-controlled phase 3 trial that assessed bevacizumab as primary and maintenance therapy for patients with newly diagnosed ovarian cancer.
In this analysis, researchers analyzed data from 1718 evaluable patients with stage 3 or 4 ovarian carcinoma. Of those, 701 patients had low volume residual, 932 had suboptimal volume residual, and 81 patients with stage 4 disease had undergone complete resection.
Results showed that time to chemotherapy initiation was associated with improved overall survival. Researchers found those who underwent complete resection had an increased risk of mortality when initiation of chemotherapy exceeded 25 days after surgery.
The American Cancer Society estimates that approximately 21 291 women with be diagnosed with ovarian cancer in the United States in 2015 and approximately 14 180 women will die from the disease.
1. Tewari KS, Java JJ, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: an NRG Oncology/Gynecologic Oncology Group Study [published online ahead of print on October 20, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv500.